Evaluation of the Kinetics of mRNA Expression After Two Doses of GSK Biologicals' Candidate Tuberculosis (TB) Vaccine GSK 692342 in Healthy Adults
Phase of Trial: Phase II
Latest Information Update: 17 Dec 2014
At a glance
- Drugs GSK 692342 (Primary)
- Indications Tuberculosis
- Focus Adverse reactions; Biomarker; Pharmacodynamics; Pharmacogenomic; Therapeutic Use
- Sponsors GlaxoSmithKline
- 07 Jun 2017 Biomarkers information updated
- 24 Nov 2014 The primary endpoints have been added which changed trial focus of study from PD, AR to TU, PD, AR as per ClinicalTrials.gov record.
- 01 May 2013 Status changed from active, no longer recruiting to completed as reported by ClinicalTrials.gov.